Anixa Biosciences Inc ANIX
Anixa Biosciences Inc (Nasdaq: ANIX) is an oncology drug developer. Its lead program, lira-cel (liraltagene autoleucel), is in Phase 1 for Recurrent epithelial ovarian cancer. Its next catalyst on record is lira-cel: Completion of Phase 1 dose-escalation study (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: lira-cel — Completion of Phase 1 dose-escalation study (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| lira-cel (chimeric endocrine receptor-T cell therapy) | Ovarian cancer | cell therapy | Phase 1 |
| Breast cancer vaccine (alpha-lactalbumin) | Triple-negative breast cancer | vaccine | Phase 1 |
| Ovarian cancer vaccine (AMHR2-ED) | Ovarian cancer | vaccine | Pre-clinical |
| Vaccine discovery program (lung, colon, prostate) | Lung, colon and prostate cancer | vaccine | Pre-clinical |
Recent results and decisions
- Dec 11, 2025positive Final phase 1 (n=35) met all major primary endpoints; protocol-defined immune responses in 74% of participants, safe at the MTD.
Final Phase 1 findings showed the investigational vaccine met all major primary endpoints, was safe and well tolerated at the maximum tolerated dose (MTD), and elicited protocol-defined immune responses in 74% of participants.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.